High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children
We examined the relation between monocyte activation markers and early and long-term neurodevelopmental outcomes in early-treated HIV-infected children.
Setting:
Prospective study of infant and child neurodevelopmental outcomes nested within a randomized clinical trial (NCT00428116) and extended cohort study in Kenya.
Methods:
HIV-infected infants (N = 67) initiated antiretroviral therapy (ART) at age
Source: JAIDS Journal of Acquired Immune Deficiency Syndromes - Category: Infectious Diseases Tags: Clinical Science Source Type: research
More News: Brain | Children | Clinical Trials | Infectious Diseases | Kenya Health | Neurology | Neuroscience | Science | Study